Business Wire

Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

Share

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare systems and improve access to healthcare for all in developing countries. As part of an annual decision-making process, Takeda employees worldwide have voted to add the Access to Health Fund and Bridges to Development as new partners for the Global CSR Program, which now supports 16 programs in more than 60 countries.

Takeda’s commitments to these new partner organizations in FY2020 include:

  • JPY 1.1 billion (USD 10.1 million*) to Access to Health Fund to help build and improve community health centers and empower health staff from ethnic health organizations and ethnic community-based health organizations (EHOs/ECBHOs) in Myanmar’s Shan State to deliver quality health services, particularly for mothers and children, over the next 5 years.
  • JPY 681 million (USD 6.3 million*) to Bridges to Development to eliminate or control 5 neglected tropical diseases in Papua New Guinea and Vanuatu including lymphatic filariasis, yaws, leprosy, trachoma, and soil-transmitted helminthiases. The 3-year project will improve health worker capacity, access to care and treatment.

“We welcome and very much value the interest that Takeda and its employees have shown in contributing to improving the health of vulnerable populations in conflict-affected and hard-to-reach areas in Shan State in Myanmar,” said Oren Ginzburg, Access to Health Fund Director.

“The Bridges team is thrilled to embark on this important work in service of communities and populations that have been frequently left behind,” said Julie Jacobson, Managing Partner & Co-Founder of Bridges to Development. “In this project, working with countries, we aim to achieve lasting health benefits through the elimination and control of several neglected tropical diseases in one innovative approach. We are thankful to Takeda employees who helped make this possible with their support.”

This year represents the 5th anniversary of Takeda’s Global CSR Program, which empowers employees in Takeda’s 80 countries of operation to be the decisionmakers for which innovative, high-impact activities receive the Company’s support. The Program, rooted in the company’s values, actively partners with world-class organizations and nongovernmental organizations (NGOs) with proven track records of addressing global health problems in effective, enduring ways to prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment for patients worldwide.

“Since its launch in 2016, Takeda’s Global CSR Program has focused on initiatives that strengthen health systems and increase access across the patient journey in low- and middle-income countries. We’re expecting to reach at least 17 million beneficiaries through 2025 globally” said Takako Ohyabu, Chief Global Corporate Affairs Officer. “We are proud to partner with the Access to Health Fund and Bridges to Development as we strive to increase health worker capacity and preventive care for patients everywhere, ensure reliable access to essential equipment and supplies, and empower communities with knowledge, services, and access to care."

In less than five years, Takeda’s Global CSR Program partners have delivered transformational impact that serves communities worldwide today and will continue to contribute to better health outcomes and stronger health systems for years to come, including:

  • JOICFP, Plan International, and UNICEF reached nearly 700,000 pregnant women and mothers, newborns, children, and adolescents, with quality health care, services, and education in sub-Saharan Africa and the Middle East.
  • JOICFP, Plan International, Seed Global Health, and UNICEF in Africa and the Middle East, with World Vision in South Asia, have collectively trained approximately 6,000 health workers in 15 countries, including qualified nurses, midwives, and physician trainees, as well as community health workers and nutrition volunteers.
  • Millions of children have been immunized against measles, and the capacity of trainings offered by academic and clinical institutions in sub-Saharan Africa has been expanded exponentially.

In line with Takeda’s core values and longstanding support for strong health systems and access to healthcare for all, Takeda recently announced contributions to the global COVID-19 response through three United Nations-led organizations to strengthen health systems, improve access to care and supplies, and address food insecurity.

Takeda also forges farsighted public-private philanthropic partnerships with game-changing multilateral and academic institutions worldwide, such as with The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the London School of Hygiene & Tropical Medicine.

* Financial information relating to the donations has been converted from JPY to USD using the ¥108.87:$1 as of June 3, 2020. For the avoidance of doubt, the amounts payable as part of the donations are denominated in JPY.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Takeda Pharmaceutical Company Limited
Ai Yoshikawa
+81(0)3-3278-3004
ai.yoshikawa@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreviPay Powers Walmart Business Pay By Invoice Offering16.9.2025 14:00:00 EEST | Press release

TreviPay, a fully managed B2B payments platform, has collaborated with Walmart Business to launch the next phase of the retailer’s Pay By Invoice program. The program enables eligible business customers to access a line of credit with 30-day net terms, powered by TreviPay’s next-generation payments and A/R automation technology. The offering is available for purchases online, in the Walmart Business app or in-store. A study of 300 global business buyers, conducted by Murphy Research for TreviPay, found 85% of buyers want the option to pay on net terms and are likely to buy more when they can pay this way. TreviPay’s Pay by Invoice offering enables buyers to defer payment, receive detailed invoices for streamlined recordkeeping and procurement, and manage cash flow more effectively. “The biggest opportunity in retail now is in B2B. Companies that capture this valuable segment will win with flexible payment options that integrate directly into the buying experience and maintain efficienc

Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma16.9.2025 14:00:00 EEST | Press release

Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with eosinophilic asthma. “More than half of people with asthma have the eosinophilic subtype, yet there remains a profound need for easily administered oral treatment options that can help address their symptoms, which are often severe,” said Ian Pavord, MA, DM, Professor of Respiratory Medicine at the University of Oxford, UK and a member of Areteia’s Scientific Advisory Board. “Initial results from the Phase III EXHALE-4 study are extremely promising, particularly the statistically significant improvement in lung function and the reduction in eosinophils observed with dexpramipexole versus placebo, which show the potential for dexpramipexole to become the first oral treatment approved for eosinophilic asthma.” “We are pleased to report positive topline results for the EXHALE-4 Phase III study, which

NIQ Joins the Decentriq Network to Enable Secure Data Collaboration for Marketers and Agencies Across Europe16.9.2025 13:00:00 EEST | Press release

NIQ, a leading consumer intelligence company, is entering a strategic relationship with Decentriq to enable data collaboration for media use cases across Europe. Through the relationship, NIQ’s high quality consumer insights, including digital purchase data, will be available in Decentriq’s privacy-preserving clean rooms for the first time, enabling advertisers and agencies to utilize the data for audience profiling and closed loop measurement. Expanding beyond shopper insights NIQ is expanding its services to the data and media ecosystem through privacy-persevering clean rooms, opening up new opportunities for marketing and advertising agencies to enrich their first-party data insights, inform audience strategies, and measure sales outcomes. As Pierre Cholet, Chief Customer Officer at Decentriq, explains, “NIQ has long been a trusted name in understanding consumer purchasing behavior. Now, by integrating their data into Decentriq’s clean room, advertisers and agencies can leverage thi

Businesses Scale Transformation to Meet Regulatory, Technology and Customer Challenges, Finds Arthur D. Little Global Research16.9.2025 12:45:00 EEST | Press release

Transformation is now a way of life for global companies, with two-thirds (65%) undergoing wide-reaching or expanding organization-wide transformation initiatives. This is driven by regulatory change (including tariffs), technological disruption, and shifting customer needs, all of which are rated at 4.1/5 in importance. Confidence levels are high, with 95% expecting initiatives to deliver success, according to the inaugural Arthur D. Little (ADL) Global Transformation Study. Time frames vary significantly between regions. 71% have a four-to-six-year window for transformation, with 32% focused on five years. However, average timelines range from 3.2 years in North America to 4.9 years in the Middle East and 5.5 years in Asia-Pacific. There are also significant differences between who leads transformation efforts globally. While a third (32%) of companies have a Chief Transformation Officer (CTrO), adoption varies considerably by region. 53% of European companies have a CTrO, compared w

Reply Achieves the AWS Advertising and Marketing Technology Competency Thanks to the Contribution of the Data Reply and Storm Reply Teams16.9.2025 11:40:00 EEST | Press release

Reply [EXM, STAR: REY] has achieved the AWS Advertising and Marketing Technology Competency, the official recognition from Amazon Web Services certifying advanced technical and project expertise in the design and delivery of advertising and marketing solutions on AWS. This milestone was made possible thanks to the joint contribution of Storm Reply and Data Reply, both part of the Reply Group, with solid expertise in implementing cloud-native and data-driven solutions on the AWS platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916374888/en/ With this certification, Reply’s companies specialized in AWS services further consolidate their role as trusted technology partners for organizations looking to evolve their marketing and communication strategies through the advanced use of AWS cloud and AI technologies. The AWS Advertising and Marketing Technology Competency validates the ability of AWS Partners to deliver hig

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye